Ischemic Stroke Market and Forecast Analysis 2024

Overview
Market Overview And Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Aspirin
Product Profile: Plavix

Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Current Treatment Options
Prescribing Trends

Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

Overview
Executive Summary
Product Overview
Product Profile: Activase
Product Profile: Aggrenox
Product Profile: Aspirin
Product Profile: Plavix

Overview
Executive Summary
Clinical Pipeline Overview
Recently Discontinued Drugs
Additional Pharma Intelligence Pipeline Resources

Figure 1: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by drug, 2016–25
Figure 3: Patient-based forecast methodology for ischemic stroke
Figure 4: Price sources and calculations, by country
Figure 5: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 6: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 7: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Figure 8: Plavix for ischemic stroke – SWOT analysis
Figure 9: The authors drug assessment summary of Plavix for ischemic stroke
Figure 10: The authors drug assessment summary of Plavix for ischemic stroke
Figure 11: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Mean percentage of patients presenting with stroke-like symptoms diagnosed with particular indications, by country, 2015
Figure 13: Mean percentage of ischemic stroke patients receiving each treatment regimen in the US, Japan, and five major EU markets, by country, 2015
Figure 14: Mean percentage of ischemic stroke patients receiving each thrombolytic therapy in the US, Japan, and five majorEU markets, by country, 2015
Figure 15: Mean percentage of ischemic stroke patients receiving each neuroprotective therapy in the US, Japan, and five major EU markets, by country, 2015
Figure 16: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the acute treatment setting, by country, 2015
Figure 17: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the secondary prevention setting at first-line, by country, 2015
Figure 18: Mean percentage of ischemic stroke patients who progress to second-line treatment in the secondary prevention setting, by country, 2015
Figure 19: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in secondary prevention setting at second-line, by country, 2015
Figure 20: Trends in diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 21: Trends in diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 22: Trend in diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 23: Trends in diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 24: Activase for ischemic stroke – SWOT analysis
Figure 25: The authors drug assessment summary of Activase for ischemic stroke
Figure 26: The authors drug assessment summary of Activase for ischemic stroke
Figure 27: Aggrenox for ischemic stroke – SWOT analysis
Figure 28: The authors drug assessment summary of Aggrenox for ischemic stroke
Figure 29: The authors drug assessment summary of Aggrenox for ischemic stroke
Figure 30: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 31: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 32: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Figure 33: Plavix for ischemic stroke – SWOT analysis
Figure 34: The authors drug assessment summary of Plavix for ischemic stroke
Figure 35: The authors drug assessment summary of Plavix for ischemic stroke
Figure 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25

Table 1: Distribution of total market sales across ischemic stroke subgroups, 2016–25
Table 2: Summary of drug classes and molecules included in The authors ischemic stroke patient-based forecast
Table 3: Patent expiries occurring within the ischemic stroke market during the forecast period, 2016–25
Table 4: Exchange rates used for calculating prices
Table 5: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
Table 6: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 7: Plavix drug profile
Table 8: Plavix pivotal trial data in ischemic stroke
Table 9: Plavix ongoing late-phase clinical trials in ischemic stroke
Table 10: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 11: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
Table 12: Overview of risk factors for a first transient ischemic attack or ischemic stroke
Table 13: Mean percentage of ischemic stroke patients that have co-morbidities in the US, Japan, and five major EU markets, by country, 2015
Table 14: Common transient ischemic attack and ischemic stroke symptoms
Table 15: Overview of tests used in ischemic stroke and transient ischemic attack patients, by major category
Table 16: Treatments available for ischemic stroke across the US, Japan, and five major EU markets
Table 17: Mean percentage of ischemic stroke patients receiving each type of therapy in the US, Japan, and five major EU markets, by country, 2015
Table 18: Overview of inclusion and exclusion criteria for patients eligible for alteplase treatment in the US
Table 19: Mean percentage of ischemic stroke patients that progress to secondary prevention in the US, Japan, and five major EU markets, by country, 2015
Table 20: Sources used for the epidemiological analysis of stroke incidence in the US, Japan, and five major EU markets, by country
Table 21: Sources used for the epidemiological analysis of stroke prevalence in the US, Japan, and five major EU markets, by country
Table 22: Diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 23: Diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 24: Diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 25: Diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 26: Key marketed drugs for ischemic stroke
Table 27: Activase drug profile
Table 28: Activase pivotal trial data in ischemic stroke
Table 29: Aggrenox drug profile
Table 30: Aggrenox pivotal trial data in ischemic stroke
Table 31: Aggrenox late-phase trial data in ischemic stroke
Table 32: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 33: Plavix drug profile
Table 34: Plavix pivotal trial data in ischemic stroke
Table 35: Plavix ongoing late-phase clinical trials in ischemic stroke
Table 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 37: Late-stage compounds that were recently discontinued for ischemic stroke
Table 38: Ampyra drug profile
Table 39: Ampyra late-phase trial data in ischemic stroke
Table 40: Brilinta drug profile
Table 41: Brilinta late-phase trial data in ischemic stroke
Table 42: Desmoteplase drug profile
Table 43: Desmoteplase late-phase trial data in ischemic stroke
Table 44: Xarelto drug profile
Table 45: Xarelto late-phase trial data in ischemic stroke